ZYNE Stock Price, Zynerba Pharmaceuticals Quote, Chart

Market Summary

USD1.30

Delayed

ZYNE Stock Price

View Fullscreen

ZYNE RSI Chart

ZYNE Valuation

Market Cap

70.1M

Price/Earnings (Trailing)

-1.87

Price/Sales (Trailing)

815.36

EV/EBITDA

-0.86

Price/Free Cashflow

-2.2

ZYNE Price/Sales (Trailing)

ZYNE Profitability

EBT Margin

-46408.34%

Return on Equity

-129.5%

Return on Assets

-92.85%

Free Cashflow Yield

-45.41%

ZYNE Fundamentals

ZYNE Revenue

Revenue (TTM)

86.0K

ZYNE Earnings

Earnings (TTM)

-37.6M

Breaking Down ZYNE Revenue

Last 7 days

0.4%

Last 30 days

-3.0%

Last 90 days

265.5%

Trailing 12 Months

74.9%

How does ZYNE drawdown profile look like?

ZYNE Financial Health

Current Ratio

3.43

ZYNE Investor Care

Shares Dilution (1Y)

17.89%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2018	0	0	0	86.0K
2016	271.3K	255.9K	56.5K	7.3K
2015	677.2K	544.5K	411.7K	278.9K
2014	910.4K	877.0K	843.5K	810.0K
2013	0	0	0	943.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zynerba Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Sep 13, 2023	anido armando	sold	-23,637	1.3257	-17,830	chairman & chief exec. officer
Sep 13, 2023	fickenscher james e	sold	-11,928	1.3257	-8,998	chief financial officer
Sep 13, 2023	sebree terri b	sold	-16,440	1.3257	-12,401	president
Sep 13, 2023	jones kenneth t	sold	-3,320	1.3257	-2,505	see remarks
Sep 13, 2023	rosenberger brian	sold	-8,499	1.3257	-6,411	vp, commercial & business dev.
Sep 12, 2023	jones kenneth t	acquired	-	-	9,000	see remarks
Sep 12, 2023	rosenberger brian	acquired	-	-	22,200	vp, commercial & business dev.
Sep 12, 2023	sebree terri b	acquired	-	-	45,000	president
Sep 12, 2023	fickenscher james e	acquired	-	-	31,200	chief financial officer
Sep 12, 2023	anido armando	acquired	-	-	64,747	chairman & chief exec. officer

Which funds bought or sold ZYNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-16,233	-	-%
Feb 26, 2024	Virtu Financial LLC	sold off	-100	-17,000	-	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	sold off	-100	-128	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-360,159	-	-%
Feb 15, 2024	GTS SECURITIES LLC	sold off	-100	-152,554	-	-%
Feb 14, 2024	Penserra Capital Management LLC	sold off	-100	-280,000	-	-%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-	-	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-413,051	-	-%
Feb 14, 2024	Creative Planning	sold off	-100	-128	-	-%
Feb 14, 2024	PenderFund Capital Management Ltd.	sold off	-100	-213,000	-	-%

Are Funds Buying or Selling ZYNE?

Are funds buying ZYNE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZYNE

No. of Funds

Unveiling Zynerba Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 08, 2024	beryl capital management llc	0%	0	SC 13G/A
Sep 05, 2023	beryl capital management llc	8.2%	4,426,381	SC 13G
Aug 24, 2023	harmony biosciences holdings, inc.	13.13%	7,592,498	SC 13D
Feb 14, 2022	etf managers group, llc	8.56%	3,526,304	SC 13G/A
Jun 01, 2021	etf managers group, llc	11.18%	4,613,332	SC 13G/A
May 11, 2021	etf managers group, llc	5.35%	2,208,784	SC 13G/A
Mar 11, 2021	etf managers group, llc	4.63%	1,910,194	SC 13G/A
Feb 10, 2021	vanguard group inc	3.52%	1,035,402	SC 13G/A
Feb 08, 2021	rapp michael	0%	0	SC 13G/A
Jan 08, 2021	etf managers group, llc	6.80%	2,000,588	SC 13G/A

Recent SEC filings of Zynerba Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
Feb 08, 2024	SC 13G/A	Major Ownership Report

Zynerba Pharmaceuticals Inc News

Latest updates

Zynerba Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2018Q4	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4
Revenue	-	0.00	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	-
Operating Expenses	-	8.00	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	-	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	697*	680*	-	-359*	-268*	0.00	-
Income Taxes	-	-	-	-	-0.06	0.00	-0.03	-	-	-	-	-	-	-	-
Earnings Before Taxes	100.0%	-	-6.90	-5.98	-6.29	-4.25	-5.41	-3.99	-1.63	-1.49	-	-	-	-	-
Net Income	-Infinity%	-7.79	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Assets	-16.8%	40.00	49.00	56.00	62.00	67.00	74.00	81.00	90.00	98.00	109	74.00	77.00	87.00	76.00	88.00	94.00	96.00	76.00	67.00	73.00	52.00
Current Assets	-17.4%	39.00	48.00	55.00	61.00	66.00	73.00	80.00	88.00	96.00	107	73.00	75.00	85.00	75.00	87.00	94.00	94.00	74.00	67.00	73.00	49.00
Cash Equivalents	-18.9%	36.00	44.00	51.00	56.00	62.00	70.00	68.00	76.00	86.00	93.00	59.00	64.00	77.00	61.00	70.00	78.00	89.00	68.00	60.00	66.00	43.00
Net PPE	-16.6%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	18.5%	11.00	10.00	9.00	10.00	10.00	9.00	10.00	11.00	10.00	13.00	14.00	11.00	13.00	10.00	12.00	9.00	10.00	7.00	10.00	9.00	12.00
Current Liabilities	19.2%	11.00	10.00	9.00	9.00	10.00	9.00	10.00	11.00	10.00	13.00	14.00	11.00	13.00	10.00	12.00	9.00	10.00	7.00	10.00	9.00	11.00
Shareholder's Equity	-25.5%	29.00	39.00	46.00	53.00	57.00	65.00	71.00	79.00	88.00	96.00	60.00	67.00	74.00	66.00	76.00	85.00	86.00	68.00	58.00	64.00	40.00
Retained Earnings	-3.8%	-295	-284	-274	-266	-257	-248	-239	-230	-220	-210	-202	-192	-183	-163	-150	-140	-138	-127	-117	-110	-102
Additional Paid-In Capital	0.3%	324	324	321	319	315	313	310	309	308	306	262	259	258	229	226	225	224	195	175	174	142
Shares Outstanding	0.8%	54.00	54.00	48.00	47.00	41.00	40.00	41.00	39.00	40.00	40.00	27.00	26.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	48.00	-	-	-	191	-	-	-	96.00	-	-	-	306	-	-	-	111

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Cashflow From Operations	-6.8%	-8,419	-7,880	-5,685	-9,658	-7,883	201	-7,834	-10,046	-7,283	-8,292	-6,986	-12,668	-10,660	-10,998	-7,464	-10,984	-6,848	-9,519	-6,207	-6,911	-8,916
Share Based Compensation	-6.5%	769	822	1,022	1,041	1,109	1,160	1,041	1,570	1,934	1,265	1,244	1,263	1,347	1,323	1,208	1,376	1,482	1,496	1,599	1,584	1,756
Cashflow From Investing	90.6%	-8.40	-89.55	-7.40	-95.10	-	-51.61	-	-	-	-	-62.09	-22.38	-222	-138	-48.34	-56.43	-	-24.62	-129	-39.84	-100
Cashflow From Financing	-100.4%	-6.71	1,729	399	3,198	675	1,741	-	-92.03	-18.08	42,266	1,895	-4.03	27,251	1,712	29.00	-72.87	27,211	18,080	-76.51	-	-

ZYNE Income Statement

2023-06-30

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
Operating expenses:
Research and development	$ 7,166,708	$ 5,446,317	$ 14,244,789	$ 10,592,922
General and administrative	3,969,499	3,722,453	7,362,593	7,479,763
Total operating expenses	11,136,207	9,168,770	21,607,382	18,072,685
Loss from operations	(11,136,207)	(9,168,770)	(21,607,382)	(18,072,685)
Other income (expense):
Interest income	434,718	91,691	882,033	187,735
Foreign exchange loss	(74,576)	(775,927)	(164,559)	(458,675)
Total other income (expense)	360,142	(684,236)	717,474	(270,940)
Net loss	$ (10,776,065)	$ (9,853,006)	$ (20,889,908)	$ (18,343,625)
Net loss per share basic	$ (0.21)	$ (0.24)	$ (0.42)	$ (0.45)
Net loss per share diluted	$ (0.21)	$ (0.24)	$ (0.42)	$ (0.45)
Basic weighted average shares outstanding	50,150,138	41,406,803	49,295,103	40,858,688
Diluted weighted average shares outstanding	50,150,138	41,406,803	49,295,103	40,858,688

ZYNE Balance Sheet

2023-06-30

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,967,515	$ 50,640,993
Incentive and tax receivables	1,308,583	1,225,383
Prepaid expenses and other current assets	2,018,874	2,908,731
Total current assets	39,294,972	54,775,107
Property and equipment, net	394,904	409,572
Incentive and tax receivables	567,648
Right-of-use assets	219,037	336,215
Total assets	40,476,561	55,520,894
Current liabilities:
Accounts payable	2,479,345	1,942,830
Accrued expenses	8,758,767	7,014,882
Lease liabilities	217,879	214,901
Total current liabilities	11,455,991	9,172,613
Lease liabilities, long-term		119,524
Total liabilities	11,455,991	9,292,137
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized; 53,939,431 shares issued and outstanding at June 30, 2023 and 47,895,687 shares issued and outstanding at December 31, 2022	53,940	47,896
Additional paid-in capital	324,373,823	320,698,146
Accumulated deficit	(295,407,193)	(274,517,285)
Total stockholders' equity	29,020,570	46,228,757
Total liabilities and stockholders' equity	$ 40,476,561	$ 55,520,894

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

CEO	Mr. Armando Anido MBA
WEBSITE	zynerba.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	25

Zynerba Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Zynerba Pharmaceuticals Inc? What does ZYNE stand for in stocks?

ZYNE is the stock ticker symbol of Zynerba Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zynerba Pharmaceuticals Inc (ZYNE)?

As of Wed Oct 11 2023, market cap of Zynerba Pharmaceuticals Inc is 70.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZYNE stock?

You can check ZYNE's fair value in chart for subscribers.

What is the fair value of ZYNE stock?

You can check ZYNE's fair value in chart for subscribers. The fair value of Zynerba Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zynerba Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZYNE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zynerba Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ZYNE is over valued or under valued. Whether Zynerba Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Zynerba Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZYNE.

What is Zynerba Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Oct 11 2023, ZYNE's PE ratio (Price to Earnings) is -1.87 and Price to Sales (PS) ratio is 815.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZYNE PE ratio will change depending on the future growth rate expectations of investors.